DC Advisory advises Care Solace on its strategic growth investment from Lemnis
Background
- Care Solace is the leading provider of mental health care coordination services for K-12 schools and municipalities. Since its commercial launch in 2018, more than 21 million individuals have accessed Care Solace’s technology and services
- LemnisTM is a philanthropic venture investing in solutions that expand learning for all, concentrating its investments in neuroscience of learning and social sciences, artificial intelligence and digital technology, and fostering a strong sense of belonging and community
Process
- DC Advisory acted as exclusive financial advisor to Care Solace on its investment from Lemnis
- DC Advisory was selected because of its deep expertise at the intersection of Education Technology and Behavioral Healthcare sectors, including relevant strategic investor relationships and process execution expertise
Outcome
- The transaction closed in February 2025
- By combining Care Solace’s experience and services with Lemnis’ commitment to learning that is more just, personal, and adaptable in a fast-moving world, Care Solace aims to deliver an expanded suite of services which will continue to develop a learner-centered system of support
- Care Solace marks Lemnis’ first strategic growth investment since its inception
- This transaction showcases DC Advisory’s expertise at the intersection of Education Technology and Behavioral Healthcare sectors
“Justin Balciunas and the DC Advisory team facilitated our investment process with integrity, thoughtfulness, and care. DC Advisory’s expertise in the Education sector was a critical contributor to the strategy. Their consistent communication, collaboration and commitment to our organization resulted in a successful transaction.”
Date
Sectors
- Education
- Technology & Software
Deal type
- M&A Advisory
Deal locations
Deal team
Managing Director
Director
UN SDG Activity
Actions
Disclaimer
For more information, please see our transaction disclaimer
For important information regarding testimonials, please see our disclaimer.